Antiangiogenic therapeutic approaches in multiple myeloma.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current Cancer Drug Targets

• Publication date

  2012-08-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/156800912802429346PMID 22780844
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma

  2012cited by this paper
• TRAF6 activation in multiple myeloma: a potential therapeutic target.

  2012cited by this paper
• The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.

  2012cited by this paper
• Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

  2012cited by this paper
• Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells

  2011cited by this paper
• Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

  2011cited by this paper
• Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma

  2011cited by this paper
• Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

  2010cited by this paper
• Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

  2010cited by this paper
• Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

  2010cited by this paper
• Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma

  2010cited by this paper
• Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

  2009cited by this paper
• Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

  2009cited by this paper
• Treatment of relapsed/refractory multiple myeloma.

  2009cited by this paper
• Front-line treatment in younger patients with multiple myeloma.

  2009cited by this paper
• The peptide‐semicarbazone S‐2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

  2009cited by this paper
• The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.

  2009cited by this paper
• Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

  2009cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.

  2008cited by this paper
• Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

  2008cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

  2008cited by this paper
• CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

  2008cited by this paper
• Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma

  2008cited by this paper
• Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.

  2008cited by this paper
• Mast Cells Contribute to Vasculogenic Mimicry in Multiple Myeloma

  2008cited by this paper
• Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

  2007cited by this paper
• Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma

  2007cited by this paper
• The history of the angiogenic switch concept

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

  2007cited by this paper
• Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.

  2006cited by this paper
• Comparing antibody and small-molecule therapies for cancer

  2006cited by this paper
• Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.

  2006cited by this paper
• United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

  2006cited by this paper
• Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

  2006cited by this paper
• A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145

  2006cited by this paper
• Bone marrow angiogenesis in multiple myeloma

  2006cited by this paper
• Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

  2006cited by this paper
• Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

  2006cited by this paper
• A phase II trial of imatinib in patients with refractory/relapsed myeloma

  2006cited by this paper
• Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

  2005cited by this paper
• Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

  2005cited by this paper
• Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

  2005cited by this paper
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

  2004cited by this paper
• GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.

  2004cited by this paper
• Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074

  2004cited by this paper
• Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

  2004cited by this paper
• Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

  2004cited by this paper
• Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

  2004cited by this paper
• Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents

  2003cited by this paper
• Vascular endothelial growth factor and its receptors in multiple myeloma

  2003cited by this paper
• In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

  2003cited by this paper
• Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

  2003cited by this paper
• RANK‐Fc in myeloma

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

  2002cited by this paper
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper
• The antitumor potential of bisphosphonates.

  2002cited by this paper
• Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid

  2002cited by this paper
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

  2001cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999cited by this paper
• High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

  1998cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Bone marrow angiogenesis and progression in multiple myeloma

  1994cited by this paper

• Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis

  2024cites this paper
• The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

  2018cites this paper
• High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

  2017cites this paper
• Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing

  2017cites this paper
• Fucoidan inhibits angiogenesis induced by multiple myeloma cells.

  2016cites this paper
• Differentiation Inducing Factor-1 Represses c-Myc and VEGF Expression in Myeloma Cells

  2016cites this paper
• MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

  2016cites this paper
• Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.

  2015cites this paper
• Targeting the bone marrow microenvironment in multiple myeloma

  2015cites this paper
• Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity

  2014cites this paper
• CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.

  2014cites this paper
• Thalidomide Embryopathy: An Enigmatic Challenge

  2013cites this paper
• Autophagy in blood cancers: biological role and therapeutic implications

  2013cites this paper
• Основные закономерности ангиогенеза при онкогематологических заболеваниях

  2013cites this paper
• Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

  2013cites this paper